◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksS › SEPN

Septerna, Inc. Common Stock (SEPN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-13

Septerna, Inc. Common Stock (SEPN) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 123 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, SEPN reported $46M in revenue and ($49M) in net income.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

Interactive charts & full statements → Open the SEPN valuation workbench →

SEPN Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-31
Total Revenue$99M$46M$1M$0M$0M
Gross Profit$98M$46M$1M$0M
Gross Margin %99.6%100.0%100.0%100.0%
Operating Income (EBIT)($44M)($81M)($81M)$2M($28M)
Operating Margin %-44.0%-175.8%-7518.4%1374.2%
Net Income($24M)($49M)($72M)$4M($28M)
Net Margin %-24.5%-106.4%-6678.9%2768.2%
EBITDA($40M)($47M)($71M)($45M)($27M)
Earnings Per Share (EPS)$-0.55$-1.10$-1.93$0.21$-1.42
Shares Outstanding (M)45M44M37M19M19M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SEPN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$27M$27M$24M$21M$0M$0M$0M$0M
Gross Profit$27M$26M$24M$21M$0M$0M$0M$0M
Gross Margin %100.0%98.4%100.0%100.0%100.0%100.0%100.0%100.0%
Operating Income (EBIT)($17M)($13M)($16M)$3M($29M)($26M)($25M)($23M)
Operating Margin %-62.9%-50.1%-66.4%12.2%-24351.3%-11831.1%-11659.4%-12812.5%
Net Income($13M)($9M)($11M)$8M($25M)($21M)($21M)($21M)
Net Margin %-48.7%-32.6%-44.5%38.0%-20872.3%-9806.4%-9749.1%-11660.8%
EBITDA($12M)($8M)($10M)($9M)($24M)($21M)($20M)($20M)
Earnings Per Share (EPS)$-0.29$-0.19$-0.24$0.18$-0.56$-0.49$-0.64$-0.49
Shares Outstanding (M)45M45M44M46M44M44M32M42M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SEPN Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-31
Cash from Operations (CFO)$106M$110M($67M)($39M)($23M)
Capital Expenditures (CapEx)$1M$1M$2M$3M$1M
Free Cash Flow (FCF)$105M$110M($70M)($42M)($25M)
FCF Margin %106.3%238.7%-6471.9%-27550.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SEPN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($22M)($26M)($15M)$169M($20M)($23M)($21M)($17M)
Capital Expenditures (CapEx)$0M$1M$0M$0M$0M$0M$1M$1M
Free Cash Flow (FCF)($22M)($26M)($15M)$169M($20M)($24M)($22M)($17M)
FCF Margin %-82.9%-99.8%-62.4%785.3%-17096.6%-10833.3%-10174.5%-9881.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SEPN Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-31
Total Assets$567M$596M$457M$131M$36M
Cash & Cash Equivalents$85M$121M$238M$88M$31M
Total Liabilities$180M$214M$37M$169M$80M
Total Debt (Short + Long-Term)$2M$2M$2M$0M$1M
Total Shareholders' Equity$387M$382M$420M($38M)($44M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SEPN viewer.

Other Companies in BIOTECHNOLOGY

← SEPMAll “S” companiesSEPP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.